interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Negotiated drugs

Medicare negotiated drugs

Medicare negotiated drugs: price, pharmacy cost and help paying

One page per drug in the CMS negotiation program, built from dated federal files and each program's own pages. The negotiated price is not what a person pays; each page says what it is and what it is not. See also the full comparison table, state insulin copay caps and state pharmaceutical assistance programs. Medicines outside the negotiation program that rank high in Medicare Part D demand are on the medicines index. Across these drugs: recent label changes, recent recalls and federal policy notices.

The drugs

  • Anoro Ellipta: selected for the 2028 cycle, negotiated price not yet published, 0 assistance programs.
  • Austedo: 13 priced packages, 0 assistance programs.
  • Biktarvy: selected for the 2028 cycle, negotiated price not yet published, 0 assistance programs.
  • Breo Ellipta: 7 priced packages, 1 assistance program.
  • Calquence: 2 priced packages, 0 assistance programs.
  • Cimzia: selected for the 2028 cycle, negotiated price not yet published, 0 assistance programs.
  • Cosentyx: selected for the 2028 cycle, negotiated price not yet published, 1 assistance program.
  • Eliquis: 12 priced packages, negotiated price 75% of the pharmacy benchmark, 4 assistance programs.
  • Enbrel: 23 priced packages, negotiated price 28% of the pharmacy benchmark, 2 assistance programs.
  • Entresto: 14 priced packages, negotiated price 45% of the pharmacy benchmark, 0 assistance programs.
  • Entyvio: selected for the 2028 cycle, negotiated price not yet published, 0 assistance programs.
  • Erleada: selected for the 2028 cycle, negotiated price not yet published, 0 assistance programs.
  • Farxiga: 17 priced packages, negotiated price 50% of the pharmacy benchmark, 0 assistance programs.
  • Ibrance: 9 priced packages, 1 assistance program.
  • Imbruvica: 8 priced packages, 0 assistance programs.
  • Janumet: 19 priced packages, 5 assistance programs.
  • Januvia: 19 priced packages, negotiated price 37% of the pharmacy benchmark, 1 assistance program.
  • Jardiance: 6 priced packages, negotiated price 61% of the pharmacy benchmark, 2 assistance programs.
  • Kisqali: selected for the 2028 cycle, negotiated price not yet published, 1 assistance program.
  • Lenvima: selected for the 2028 cycle, negotiated price not yet published, 0 assistance programs.
  • Linzess: 3 priced packages, 0 assistance programs.
  • Novolog: 17 priced packages, negotiated price 100% of the pharmacy benchmark, 2 assistance programs.
  • Ofev: 2 priced packages, 0 assistance programs.
  • Orencia: selected for the 2028 cycle, negotiated price not yet published, 0 assistance programs.
  • Otezla: 14 priced packages, 1 assistance program.
  • Ozempic: 38 priced packages, 4 assistance programs.
  • Pomalyst: 8 priced packages, 0 assistance programs.
  • Rexulti: selected for the 2028 cycle, negotiated price not yet published, 0 assistance programs.
  • Stelara: 9 priced packages, negotiated price 30% of the pharmacy benchmark, 1 assistance program.
  • Tradjenta: 4 priced packages, 1 assistance program.
  • Trelegy Ellipta: 4 priced packages, 1 assistance program.
  • Trulicity: selected for the 2028 cycle, negotiated price not yet published, 1 assistance program.
  • Verzenio: selected for the 2028 cycle, negotiated price not yet published, 1 assistance program.
  • Vraylar: 26 priced packages, 0 assistance programs.
  • Xarelto: 19 priced packages, negotiated price 35% of the pharmacy benchmark, 3 assistance programs.
  • Xeljanz: selected for the 2028 cycle, negotiated price not yet published, 0 assistance programs.
  • Xifaxan: 8 priced packages, 0 assistance programs.
  • Xolair: selected for the 2028 cycle, negotiated price not yet published, 1 assistance program.
  • Xtandi: 3 priced packages, 0 assistance programs.

How these pages are built

Each page reads one library of dated facts: the CMS negotiated-price file, CMS NADAC, the assistance programs' own pages, FDA application and label data, FDA enforcement reports and ClinicalTrials.gov. A page appears only when at least two of those layers hold facts for the drug, and a drug CMS has selected but not yet priced shows no price. Every figure carries its source and date, and the negotiated price is never presented as a patient price. Where every figure comes from. Licence the data.

For developers: every page as data

The index lists every file: one dossier per negotiated drug, findings, a change feed and the termination calendar, each with receipts.

Example file: https://omnirx.org/api/v1/index.json

The licence page sets out what a data licence covers, and the API page documents these files.

Evaluation files with receipts; contract may change; not clinical advice.